ADDITIONAL INFORMATION CONTINUED EQUITY SECURITIES INFORMATION The Company has only one class of shares, being ordinary shares. Each ordinary share is entitled to one vote when a poll is called; otherwise on a show of hands at a shareholder meeting every member present in person or by proxy has one vote. There are no securities subject to escrow. On 11 February 2026, the Company commenced an on-market share buy-back program, The on-market share buy-back program has a buy-back period of up to 12 months and will not exceed 5% of the total shares on issue in Neuren as at the date 12 months prior to the commencement of the buy-back. The following information is based on share registry information processed up to and including 16 March 2026. The number of ordinary shareholdings held in less than marketable parcels at 16 March 2026 was 1,111, holding 26,840 ordinary shares. DISTRIBUTION OF SECURITY HOLDERS Listed ordinary shares Size of holding Number of ordinary shares % Number of holders % 100,001 and Over 89,294,755 70.57 115 0.97 10,001 to 100,000 23,045,623 18.21 790 6.65 5,001 to 10,000 4,730,560 3.74 637 5.37 1,001 to 5,000 7,087,699 5.60 2,888 24.33 1 to 1,000 2,374,989 1.88 7,441 62.68 Total 126,533,626 100.00 11,871 100.00 UNLISTED SECURITIES 2,885,000 Employee Share Scheme options, with a weighted average exercise price of $12.88, of which 450,000 have an expiry date of 8 July 2026, 260,000 have an expiry date of 7 February 2029, 1,800,000 have an expiry date of 23 May 2030, 210,000 have an expiry date of 9 July 2030 and 165,000 have an expiry date of 19 September 2030. There are 12 holders of 100,001 and over. Neuren Pharmaceuticals Limited Annual Report 2025 63
RkJQdWJsaXNoZXIy MjE2NDg3